Leonie S. Taams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Leonie S. Taams has a total of 705 co-authors. Here are the top co-authors by number of shared publications:
- Bruce Kirkham
Department of Rheumatology, Guy’s and St Thomas’ NHS Foundation Trust
12 shared publications Hayley G. Evans
Peter Gorer Department of Immunobiology, Division of Immunology, Infection and Inflammatory Disease, King’s College London, London, United Kingdom
12 shared publications- Marca H. M. Wauben
Utrecht University
12 shared publications Bruce W. Kirkham
Department of Rheumatology, Guy’s Hospital, London, UK
9 shared publicationsBina Menon
Guy's and St Thomas’ NHS Trust London United Kingdom
8 shared publications- Franziska Denk
Wolfson Sensory, Pain and Regeneration Centre (SPaRC), King’s College London, London, UK
8 shared publications
Latest Publications
- Open Access
Refinement of the Pathogenic T Cell Receptor Motif Suggests Type 17 CD8+ T Cells Initiate HLA-B*27-associated Autoimmunity
Human leukocyte antigen B*27 (HLA-B*27) is a major risk factor for autoimmune diseases such as axial spondyloarthritis (axSpA), acute anterior uveitis (AAU), and psoriatic arthritis (PsA). HLA-B*27 presents bacterial and self-antigens to disease-associated CD8+ T cells, however, how this leads to a pathogenic IL-17-mediated disease remains unclear. We performed mutational experiments in an established disease-associated TCR and demonstrated that the pathogenic motif encompasses a wider range of TCR sequences than previously appreciated. We next leveraged computational pairing of alpha/beta TCR sequencing (TCR-seq) to demonstrate that the broadened pathogenic motif distinguishes axSpA and AAU patients from healthy controls. Paired single-cell RNA sequencing and single-cell TCR sequencing datasets demonstrated that the pathogenic cells have a distinct transcriptional signature. We find a coupling of pathogenic TCRs to this transcriptional signature in public datasets from axSpA and PsA joint fluid and AAU ocular fluid. Finally, we detect the pathogenic CD8+ T cells in the gut and demonstrate that they express a Type 17 program. Our findings suggest that HLA-B*27+ axSpA, AAU, and PsA are initiated by HLA-B*27-restricted pathogenic CD8+ T cells that undergo Type 17 differentiation in response to intestinal antigens. One Sentence Summary: Multiple HLA-B*27-associated autoimmune diseases share the same pathogenic CD8+ T cells with Type 17 gene expression and cytokine production.
Open AccessRefinement of the Pathogenic T Cell Receptor Motif Suggests Type 17 CD8+ T Cells Initiate HLA-B*27-associated Autoimmunity
Human leukocyte antigen B*27 (HLA-B*27) is a major risk factor for autoimmune diseases such as axial spondyloarthritis (axSpA), acute anterior uveitis (AAU), and psoriatic arthritis (PsA). HLA-B*27 presents bacterial and self-antigens to disease-associated CD8+ T cells, however, how this leads to a pathogenic IL-17-mediated disease remains unclear. We performed mutational experiments in an established disease-associated TCR and demonstrated that the pathogenic motif encompasses a wider range of TCR sequences than previously appreciated. We next leveraged computational pairing of alpha/beta TCR sequencing (TCR-seq) to demonstrate that the broadened pathogenic motif distinguishes axSpA and AAU patients from healthy controls. Paired single-cell RNA sequencing and single-cell TCR sequencing datasets demonstrated that the pathogenic cells have a distinct transcriptional signature. We find a coupling of pathogenic TCRs to this transcriptional signature in public datasets from axSpA and PsA joint fluid and AAU ocular fluid. Finally, we detect the pathogenic CD8+ T cells in the gut and demonstrate that they express a Type 17 program. Our findings suggest that HLA-B*27+ axSpA, AAU, and PsA are initiated by HLA-B*27-restricted pathogenic CD8+ T cells that undergo Type 17 differentiation in response to intestinal antigens. One Sentence Summary: Multiple HLA-B*27-associated autoimmune diseases share the same pathogenic CD8+ T cells with Type 17 gene expression and cytokine production.
- Open Access
- 2 September 2026
- Published by Wolters Kluwer Health in Pain
Centrally mediated pain features predict persistent pain in early inflammatory arthritis: a 2-year prospective study
Patients with inflammatory arthritis (IA) often report pain not necessarily coupled to active inflammation. We previously demonstrated that a significant subset of patients with newly diagnosed IA report features of centrally mediated pain. In this prospective study following the same IA cohort, we tracked the relative contributions of inflammatory/noninflammatory mechanisms to pain over 2 years. We used patient-reported outcome measures (PROMs), clinical data (including ultrasound), and standardised quantitative sensory testing. Mixed-effects regression models examined longitudinal associations. We recruited 66 patients. At 6, 12, and 24 months, 62%, 57%, and 49% of individuals, respectively, reported persistent pain (numerical rating scale ≥3). Using factor-derived composite scores, baseline and longitudinal inflammation was not associated with subsequent pain ( b −0.05, P = 0.87), whereas higher centrally mediated pain markers predicted less pain reduction ( b 1.41, 95%, P < 0.001). Baseline PROMs of centrally mediated pain (fibromyalgia severity average marginal effect [AME]: 0.94, P < 0.001, painDETECT AME: 1.03, P < 0.001) and mental health (eg, Generalised Anxiety Disorder-7 AME: 1.08, P < 0.001) were the strongest predictors of persistent pain. Baseline trapezius pressure pain threshold (PPT) and conditioned pain modulation (CPM) pain detection threshold (PDT) effect showed modest association (trapezius PPT AME: −0.51, P = 0.054, CPM PDT effect AME: −0.49, P = 0.051) whereas temporal summation of pain (AME: 0.09, P = 0.756) and CPM pain tolerance threshold effect (AME: −0.01, P = 0.964) did not. In our cohort, persistent pain was associated with higher baseline and longitudinal scores for centrally mediated pain according to PROMs rather than inflammation according to joint ultrasound. In IA, early identification and treatment of features of centrally mediated pain may improve pain-related outcomes.
- 2 September 2026
- Published by Wolters Kluwer Health in Pain
Open AccessCentrally mediated pain features predict persistent pain in early inflammatory arthritis: a 2-year prospective study
Patients with inflammatory arthritis (IA) often report pain not necessarily coupled to active inflammation. We previously demonstrated that a significant subset of patients with newly diagnosed IA report features of centrally mediated pain. In this prospective study following the same IA cohort, we tracked the relative contributions of inflammatory/noninflammatory mechanisms to pain over 2 years. We used patient-reported outcome measures (PROMs), clinical data (including ultrasound), and standardised quantitative sensory testing. Mixed-effects regression models examined longitudinal associations. We recruited 66 patients. At 6, 12, and 24 months, 62%, 57%, and 49% of individuals, respectively, reported persistent pain (numerical rating scale ≥3). Using factor-derived composite scores, baseline and longitudinal inflammation was not associated with subsequent pain ( b −0.05, P = 0.87), whereas higher centrally mediated pain markers predicted less pain reduction ( b 1.41, 95%, P < 0.001). Baseline PROMs of centrally mediated pain (fibromyalgia severity average marginal effect [AME]: 0.94, P < 0.001, painDETECT AME: 1.03, P < 0.001) and mental health (eg, Generalised Anxiety Disorder-7 AME: 1.08, P < 0.001) were the strongest predictors of persistent pain. Baseline trapezius pressure pain threshold (PPT) and conditioned pain modulation (CPM) pain detection threshold (PDT) effect showed modest association (trapezius PPT AME: −0.51, P = 0.054, CPM PDT effect AME: −0.49, P = 0.051) whereas temporal summation of pain (AME: 0.09, P = 0.756) and CPM pain tolerance threshold effect (AME: −0.01, P = 0.964) did not. In our cohort, persistent pain was associated with higher baseline and longitudinal scores for centrally mediated pain according to PROMs rather than inflammation according to joint ultrasound. In IA, early identification and treatment of features of centrally mediated pain may improve pain-related outcomes.
- Open Access
Fibroblast–Neuron interactions Driving persistent Pain in Rheumatoid Arthritis (FiND-Pain RA) – an observational study protocol
Introduction: Pain in patients with rheumatoid arthritis (RA) is an unmet clinical need. Targeting joint inflammation with disease-modifying antirheumatic drugs has not resulted in the anticipated reduction in pain for many patients. This can partly be explained by the concept of central sensitisation whereby spinal and supraspinal pathways have a lower threshold of activation, leading to increased perception of pain. Synovial stromal cells, such as fibroblasts, are also thought to play a role through peripheral sensitisation of nerves in the joint. Synovial fibroblasts are known to produce pro-algesic mediators such as interleukin 6 and nerve growth factor at the messenger RNA level. These pro-algesic mediators could activate sensory nerve fibres that send signals from the joint to the spinal cord, thereby driving persistent pain in RA. The purpose of this study is to evaluate which pro-algesic mediators are produced by lining versus sub-lining fibroblasts and whether the level of these mediators correlates with clinical measures of pain in patients with RA. Methods and analysis: FiND-Pain RA is a multicentre observational study which will recruit 50 patients with seropositive RA who attend the rheumatology department of Guy’s and St Thomas’ Hospital, London, and the Nuffield Orthopaedic Centre, Oxford. Clinical examination, pain-focused patient-reported outcome measures, ultrasound examination and ultrasound-guided synovial biopsy of the knee will be performed. The levels of known and putative pro-algesic mediators will be measured in fibroblasts from the lining and sub-lining layer of the synovium. The location and spatial morphology of sensory nerve fibres and their proximity to lining and sub-lining fibroblasts will be characterised. The primary outcome will be to determine whether the knee pain scores of participants correlate with the level of leukaemia inhibitory factor, a novel putative pain-mediator expressed in sub-lining fibroblasts. The secondary outcomes will be to determine whether other pro-algesic mediators produced by lining or sub-lining fibroblasts correlate with clinical measures of pain and to assess the location and proximity of sensory nerve fibres to lining versus sub-lining fibroblasts. Ethics and dissemination: The study is a sub-study of the PUMIA (Pain Phenotypes and their Underlying Mechanisms in Inflammatory Arthritis) study, which has been approved by the Bromley Research Ethics Committee (REC: 21/LO/0712). The findings of this study will be disseminated through open-access publications, as well as scientific and clinical conferences.
Open AccessFibroblast–Neuron interactions Driving persistent Pain in Rheumatoid Arthritis (FiND-Pain RA) – an observational study protocol
Introduction: Pain in patients with rheumatoid arthritis (RA) is an unmet clinical need. Targeting joint inflammation with disease-modifying antirheumatic drugs has not resulted in the anticipated reduction in pain for many patients. This can partly be explained by the concept of central sensitisation whereby spinal and supraspinal pathways have a lower threshold of activation, leading to increased perception of pain. Synovial stromal cells, such as fibroblasts, are also thought to play a role through peripheral sensitisation of nerves in the joint. Synovial fibroblasts are known to produce pro-algesic mediators such as interleukin 6 and nerve growth factor at the messenger RNA level. These pro-algesic mediators could activate sensory nerve fibres that send signals from the joint to the spinal cord, thereby driving persistent pain in RA. The purpose of this study is to evaluate which pro-algesic mediators are produced by lining versus sub-lining fibroblasts and whether the level of these mediators correlates with clinical measures of pain in patients with RA. Methods and analysis: FiND-Pain RA is a multicentre observational study which will recruit 50 patients with seropositive RA who attend the rheumatology department of Guy’s and St Thomas’ Hospital, London, and the Nuffield Orthopaedic Centre, Oxford. Clinical examination, pain-focused patient-reported outcome measures, ultrasound examination and ultrasound-guided synovial biopsy of the knee will be performed. The levels of known and putative pro-algesic mediators will be measured in fibroblasts from the lining and sub-lining layer of the synovium. The location and spatial morphology of sensory nerve fibres and their proximity to lining and sub-lining fibroblasts will be characterised. The primary outcome will be to determine whether the knee pain scores of participants correlate with the level of leukaemia inhibitory factor, a novel putative pain-mediator expressed in sub-lining fibroblasts. The secondary outcomes will be to determine whether other pro-algesic mediators produced by lining or sub-lining fibroblasts correlate with clinical measures of pain and to assess the location and proximity of sensory nerve fibres to lining versus sub-lining fibroblasts. Ethics and dissemination: The study is a sub-study of the PUMIA (Pain Phenotypes and their Underlying Mechanisms in Inflammatory Arthritis) study, which has been approved by the Bromley Research Ethics Committee (REC: 21/LO/0712). The findings of this study will be disseminated through open-access publications, as well as scientific and clinical conferences.
- Open Access
- 7 October 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (1) , 154-163
Assessment of Pain Types in Recently Diagnosed Patients With Inflammatory Arthritis
Objective: Up to 40% of patients with inflammatory arthritis (IA) experience persistent pain, traditionally thought to be associated with a shift from peripherally to centrally mediated pain during the disease course in some patients. We assessed sensory profiles of recently diagnosed individuals with IA, hypothesizing that pain reported at this early stage of diagnosis is driven predominantly by peripheral joint inflammation. Methods: Recently diagnosed patients with IA with pain numerical rating scale scores of ≥3 were recruited. We collected data on the following: arthritis activity (Disease Activity Score in 28 joints [DAS28], musculoskeletal ultrasonography), quality of life (Musculoskeletal Health Questionnaire [MSK‐HQ], EuroQol 5‐domain), mental health status (Patient Health Questionnaire Anxiety–Depression Scale [PHQ‐ADS]), and pain characteristics (fibromyalgia criteria, painDETECT, static and dynamic quantitative sensory testing [QST]). Results: Sixty‐one participants (57% female, 62% with rheumatoid arthritis) were enrolled (mean ± SD age 49.8 ± 15 years; mean ± SD time since diagnosis 1.2 ± 2.3 months). Ninety‐seven percent had peripheral joint inflammation, with a mean ± SD DAS28 score of 3.8 ± 1. However, 21% met the fibromyalgia criteria, 25% had a painDETECT score of ≥19, and 20% had a tender joint count minus swollen joint count of ≥7, which significantly correlated with DAS28, MSK‐HQ, and PHQ‐ADS scores. QST revealed lowered pressure pain thresholds at nonarticular sites in a subset of participants and facilitated temporal pain summation and deficient pain modulation in 18% and 61% of patients, respectively. Conclusion: This study provides evidence of centrally mediated pain at the time of diagnosis, challenging the notion that, even at the early stage of disease, pain is driven only by peripheral mechanisms.
- 7 October 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (1) , 154-163
Open AccessAssessment of Pain Types in Recently Diagnosed Patients With Inflammatory Arthritis
Objective: Up to 40% of patients with inflammatory arthritis (IA) experience persistent pain, traditionally thought to be associated with a shift from peripherally to centrally mediated pain during the disease course in some patients. We assessed sensory profiles of recently diagnosed individuals with IA, hypothesizing that pain reported at this early stage of diagnosis is driven predominantly by peripheral joint inflammation. Methods: Recently diagnosed patients with IA with pain numerical rating scale scores of ≥3 were recruited. We collected data on the following: arthritis activity (Disease Activity Score in 28 joints [DAS28], musculoskeletal ultrasonography), quality of life (Musculoskeletal Health Questionnaire [MSK‐HQ], EuroQol 5‐domain), mental health status (Patient Health Questionnaire Anxiety–Depression Scale [PHQ‐ADS]), and pain characteristics (fibromyalgia criteria, painDETECT, static and dynamic quantitative sensory testing [QST]). Results: Sixty‐one participants (57% female, 62% with rheumatoid arthritis) were enrolled (mean ± SD age 49.8 ± 15 years; mean ± SD time since diagnosis 1.2 ± 2.3 months). Ninety‐seven percent had peripheral joint inflammation, with a mean ± SD DAS28 score of 3.8 ± 1. However, 21% met the fibromyalgia criteria, 25% had a painDETECT score of ≥19, and 20% had a tender joint count minus swollen joint count of ≥7, which significantly correlated with DAS28, MSK‐HQ, and PHQ‐ADS scores. QST revealed lowered pressure pain thresholds at nonarticular sites in a subset of participants and facilitated temporal pain summation and deficient pain modulation in 18% and 61% of patients, respectively. Conclusion: This study provides evidence of centrally mediated pain at the time of diagnosis, challenging the notion that, even at the early stage of disease, pain is driven only by peripheral mechanisms.
- Open Access
- 21 September 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (1) , 152-165
Linking Skin and Joint Inflammation in Psoriatic Arthritis through Shared CD8 + T Cell Clones
Objective: Psoriatic arthritis (PsA) is an HLA class I–associated inflammatory arthritis that develops in up to 30% of people with psoriasis. We tested the hypothesis that skin and joint inflammation in PsA is linked in terms of CD8 + T cell phenotype and clonality. Methods: Using single‐cell RNA sequencing (n = 6 skin samples with n = 5 paired synovial tissue samples and/or n = 5 paired synovial fluid samples) and spatial transcriptomics (n = 1 paired skin and synovial biopsy sample, n = 4 unpaired biopsy samples), we compared the transcriptional signature, T cell receptor repertoire, and cell neighborhoods of T cells from skin and synovial tissue and/or fluid samples from patients with PsA. Results: We identified an enrichment of type 17 CD8 + tissue‐resident memory T (Trm) cells in both the skin and joint, with a stronger interleukin‐17 signature in the skin than the joint. CD8 + Trm cells resided in distinct cell neighborhoods in the skin and joint but were located adjacent to antigen‐presenting cells in both sites. Several T cell clones were shared between the skin and joint. Across the six patients, 155 CD8 + T cell clones were shared between the two sites, comprising 1,071 CD8 + T cells and taking up a median of 13% of the skin and 8% of the joint CD8 + T cell receptor repertoire. CD8 + skin–joint shared clones tended to have a similar phenotype at both sites, characterized by increased expression of genes associated with a cytotoxic, tissue‐resident phenotype. Conclusion: Our findings support the hypothesis that skin and joint inflammation in PsA is linked in terms of CD8 + T cell clonality and that specific T cells migrate between these compartments to propagate inflammation across both sites.
- 21 September 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (1) , 152-165
Open AccessLinking Skin and Joint Inflammation in Psoriatic Arthritis through Shared CD8 + T Cell Clones
Objective: Psoriatic arthritis (PsA) is an HLA class I–associated inflammatory arthritis that develops in up to 30% of people with psoriasis. We tested the hypothesis that skin and joint inflammation in PsA is linked in terms of CD8 + T cell phenotype and clonality. Methods: Using single‐cell RNA sequencing (n = 6 skin samples with n = 5 paired synovial tissue samples and/or n = 5 paired synovial fluid samples) and spatial transcriptomics (n = 1 paired skin and synovial biopsy sample, n = 4 unpaired biopsy samples), we compared the transcriptional signature, T cell receptor repertoire, and cell neighborhoods of T cells from skin and synovial tissue and/or fluid samples from patients with PsA. Results: We identified an enrichment of type 17 CD8 + tissue‐resident memory T (Trm) cells in both the skin and joint, with a stronger interleukin‐17 signature in the skin than the joint. CD8 + Trm cells resided in distinct cell neighborhoods in the skin and joint but were located adjacent to antigen‐presenting cells in both sites. Several T cell clones were shared between the skin and joint. Across the six patients, 155 CD8 + T cell clones were shared between the two sites, comprising 1,071 CD8 + T cells and taking up a median of 13% of the skin and 8% of the joint CD8 + T cell receptor repertoire. CD8 + skin–joint shared clones tended to have a similar phenotype at both sites, characterized by increased expression of genes associated with a cytotoxic, tissue‐resident phenotype. Conclusion: Our findings support the hypothesis that skin and joint inflammation in PsA is linked in terms of CD8 + T cell clonality and that specific T cells migrate between these compartments to propagate inflammation across both sites.
- Open Access
- 9 July 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (11) , 2249-2254
Methotrexate and ciclosporin both reduce levels of circulating interleukin (IL)-4 and IL-13 expressing CD4+ memory T cells in childhood atopic dermatitis
Atopic dermatitis (AD) is a chronic dermatosis characterized by type-2 inflammatory responses, skin barrier anomalies and microbiome dysregulation. The variety of AD presentations necessitates a better understanding of the underlying disease mechanisms and the modulation of immune markers over a treatment course. Globally, the most used systemic therapies for moderate-to-severe AD are methotrexate (MTX) and ciclosporin (CyA). The TReatment of severe Atopic Eczema in children Trial (TREAT) was a randomized controlled trial (RCT) assessing the efficacy and safety of MTX and CyA. Peripheral blood samples from 18 TREAT participants were analysed in a longitudinal immunological study with a focus on cytokine-expressing CD4+ T cells. The analysis showed that both MTX and CyA were associated with a decreased percentage of interleukin (IL)-4 and IL-13 expressing CD4+ memory T cells, corresponding to improved disease severity. Patients receiving MTX experienced a more sustained decrease in IL-4 expressing T cells, which corresponds to the longer-term improved disease control observed in the MTX arm.
- 9 July 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (11) , 2249-2254
Open AccessMethotrexate and ciclosporin both reduce levels of circulating interleukin (IL)-4 and IL-13 expressing CD4+ memory T cells in childhood atopic dermatitis
Atopic dermatitis (AD) is a chronic dermatosis characterized by type-2 inflammatory responses, skin barrier anomalies and microbiome dysregulation. The variety of AD presentations necessitates a better understanding of the underlying disease mechanisms and the modulation of immune markers over a treatment course. Globally, the most used systemic therapies for moderate-to-severe AD are methotrexate (MTX) and ciclosporin (CyA). The TReatment of severe Atopic Eczema in children Trial (TREAT) was a randomized controlled trial (RCT) assessing the efficacy and safety of MTX and CyA. Peripheral blood samples from 18 TREAT participants were analysed in a longitudinal immunological study with a focus on cytokine-expressing CD4+ T cells. The analysis showed that both MTX and CyA were associated with a decreased percentage of interleukin (IL)-4 and IL-13 expressing CD4+ memory T cells, corresponding to improved disease severity. Patients receiving MTX experienced a more sustained decrease in IL-4 expressing T cells, which corresponds to the longer-term improved disease control observed in the MTX arm.
- Open Access
- 6 May 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (12)
Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons
JAK inhibitors (JAKi) are widely used antiinflammatory drugs. Recent data suggest that JAKi have superior effects on pain reduction in rheumatoid arthritis (RA). However, the underlying mechanisms for this observation are not fully understood. We investigated whether JAKi can act directly on human sensory neurons. We analyzed RNA-seq datasets of sensory neurons and found that they expressed JAK1 and STAT3. Addition of cell-free RA synovial fluid to human induced pluripotent stem cell–derived (iPSC-derived) sensory neurons led to phosphorylation of STAT3 (pSTAT3), which was completely blocked by the JAKi tofacitinib. Compared with paired serum, RA synovial fluid was enriched for the STAT3 signalling cytokines IL-6, IL-11, LIF, IFN-α, and IFN-β, with their requisite receptors present in peripheral nerves postmortem. Accordingly, these recombinant cytokines induced pSTAT3 in iPSC-derived sensory neurons. Furthermore, IL-6 + sIL-6R and LIF upregulated expression of pain-relevant genes with STAT3-binding sites, an effect that was blocked by tofacitinib. LIF also induced neuronal sensitization, highlighting this molecule as a putative pain mediator. Finally, over time, tofacitinib reduced the firing rate of sensory neurons stimulated with RA synovial fluid. Together, these data indicate that JAKi can act directly on human sensory neurons, providing a potential mechanistic explanation for their suggested superior analgesic properties.
- 6 May 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (12)
Open AccessRheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons
JAK inhibitors (JAKi) are widely used antiinflammatory drugs. Recent data suggest that JAKi have superior effects on pain reduction in rheumatoid arthritis (RA). However, the underlying mechanisms for this observation are not fully understood. We investigated whether JAKi can act directly on human sensory neurons. We analyzed RNA-seq datasets of sensory neurons and found that they expressed JAK1 and STAT3. Addition of cell-free RA synovial fluid to human induced pluripotent stem cell–derived (iPSC-derived) sensory neurons led to phosphorylation of STAT3 (pSTAT3), which was completely blocked by the JAKi tofacitinib. Compared with paired serum, RA synovial fluid was enriched for the STAT3 signalling cytokines IL-6, IL-11, LIF, IFN-α, and IFN-β, with their requisite receptors present in peripheral nerves postmortem. Accordingly, these recombinant cytokines induced pSTAT3 in iPSC-derived sensory neurons. Furthermore, IL-6 + sIL-6R and LIF upregulated expression of pain-relevant genes with STAT3-binding sites, an effect that was blocked by tofacitinib. LIF also induced neuronal sensitization, highlighting this molecule as a putative pain mediator. Finally, over time, tofacitinib reduced the firing rate of sensory neurons stimulated with RA synovial fluid. Together, these data indicate that JAKi can act directly on human sensory neurons, providing a potential mechanistic explanation for their suggested superior analgesic properties.
- Open Access
Assessment of pain types in recently diagnosed patients with inflammatory arthritis
Objective: Up to 40% of patients with inflammatory arthritis (IA) experience persistent pain, traditionally thought to be associated with a shift from peripheral to centrally mediated pain during the disease course in some patients. We assessed sensory profiles of recently diagnosed individuals with IA, hypothesising that pain reported at this early stage of diagnosis is driven predominantly by peripheral joint inflammation. Methods: Recently diagnosed IA patients with pain numerical rating scale (NRS) scores of ≥3 were recruited. We collected data on: Arthritis activity (Disease Activity Score-28 (DAS-28), musculoskeletal ultrasound); quality of life (Musculoskeletal Health questionnaire (MSK-HQ), Euro Quality of Life questionnaire (EQ-5D)); mental health status (Patient Health Questionnaire Anxiety, Depression Scale (PHQ-ADS)), and pain characteristics (fibromyalgia criteria, painDETECT, Static and Dynamic Quantitative Sensory Testing, QST). Results: 61 participants (57% female, 62% rheumatoid arthritis) were enrolled: mean age 49.8 ±15; time since diagnosis 1.2±2.3 months. 97% had peripheral joint inflammation, with a mean DAS-28 score of 3.8±1. However, 20% had a tender minus swollen joint count of ≥7, 21% met the fibromyalgia criteria and 25% had a painDETECT score of ≥19, which significantly correlated with DAS28, MSK-HQ and PHQ-ADS scores. QST revealed lowered pressure pain thresholds at non-articular sites in a subset of participants and facilitated temporal pain summation and deficient pain modulation in 18% and 61% of patients respectively. Conclusion: This study provides evidence of centrally mediated pain at the time of diagnosis, challenging the notion that, even at the early stage of disease, pain is driven only by peripheral mechanisms. SIGNIFICANCE AND INNOVATIONS: This study is the first to record comprehensive sensory profiles incorporating clinical examination, ultrasound, questionnaire, and quantitative sensory testing data in the early stage of inflammatory arthritis diagnosis. Of those tested, 97% had peripheral joint inflammation confirmed by clinical assessment and ultrasound. In addition, clinical, patient-reported and QST outcome measures revealed the likely presence of centrally mediated pain in a subset of participants. These findings challenge the current belief that only peripheral mechanisms driven by joint inflammation underpin pain in the early stage of disease progression, highlighting a role for centrally mediated pain even in the early stage of disease.
Open AccessAssessment of pain types in recently diagnosed patients with inflammatory arthritis
Objective: Up to 40% of patients with inflammatory arthritis (IA) experience persistent pain, traditionally thought to be associated with a shift from peripheral to centrally mediated pain during the disease course in some patients. We assessed sensory profiles of recently diagnosed individuals with IA, hypothesising that pain reported at this early stage of diagnosis is driven predominantly by peripheral joint inflammation. Methods: Recently diagnosed IA patients with pain numerical rating scale (NRS) scores of ≥3 were recruited. We collected data on: Arthritis activity (Disease Activity Score-28 (DAS-28), musculoskeletal ultrasound); quality of life (Musculoskeletal Health questionnaire (MSK-HQ), Euro Quality of Life questionnaire (EQ-5D)); mental health status (Patient Health Questionnaire Anxiety, Depression Scale (PHQ-ADS)), and pain characteristics (fibromyalgia criteria, painDETECT, Static and Dynamic Quantitative Sensory Testing, QST). Results: 61 participants (57% female, 62% rheumatoid arthritis) were enrolled: mean age 49.8 ±15; time since diagnosis 1.2±2.3 months. 97% had peripheral joint inflammation, with a mean DAS-28 score of 3.8±1. However, 20% had a tender minus swollen joint count of ≥7, 21% met the fibromyalgia criteria and 25% had a painDETECT score of ≥19, which significantly correlated with DAS28, MSK-HQ and PHQ-ADS scores. QST revealed lowered pressure pain thresholds at non-articular sites in a subset of participants and facilitated temporal pain summation and deficient pain modulation in 18% and 61% of patients respectively. Conclusion: This study provides evidence of centrally mediated pain at the time of diagnosis, challenging the notion that, even at the early stage of disease, pain is driven only by peripheral mechanisms. SIGNIFICANCE AND INNOVATIONS: This study is the first to record comprehensive sensory profiles incorporating clinical examination, ultrasound, questionnaire, and quantitative sensory testing data in the early stage of inflammatory arthritis diagnosis. Of those tested, 97% had peripheral joint inflammation confirmed by clinical assessment and ultrasound. In addition, clinical, patient-reported and QST outcome measures revealed the likely presence of centrally mediated pain in a subset of participants. These findings challenge the current belief that only peripheral mechanisms driven by joint inflammation underpin pain in the early stage of disease progression, highlighting a role for centrally mediated pain even in the early stage of disease.
- Open Access
- 25 February 2025
- Published by Wolters Kluwer Health in Pain
- Vol. 166 (7) , 1662-1679
Modelling inflammation-induced peripheral sensitization in a dish—more complex than expected?
Peripheral sensitization of nociceptors is believed to be a key driver of chronic pain states. Here, we sought to study the effects of a modified version of inflammatory soup on the excitability of human stem cell–derived sensory neurons. For this, we used a preexisting and a novel stem cell line, modified to stably express the calcium sensor GCamP6f. Upon treatment with inflammatory soup, we observed no changes in neuronal transcription or functional responses upon calcium imaging and only a very minor increase in resting membrane potential (RMP) via whole cell patch clamping: control RMP (−71.31 ± 1.1 mV) vs inflammatory soup RMP (−67.74 ± 1.29 mV), uncorrected 2-tailed independent samples t test, P = 0.0383. Similarly, small changes were observed when treating mouse primary sensory neurons with inflammatory soup. A semi-systematic reexamination of past literature further indicated that observed effects of inflammatory mediators on dissociated sensory neuron cultures are generally small. We conclude that modelling inflammation-induced peripheral sensitization in vitro is nontrivial and will require careful selection of mediators and/or more complex, longitudinal multicellular setups. Especially in the latter, our novel GCamP6f-induced pluripotent stem cell line may be of value.
- 25 February 2025
- Published by Wolters Kluwer Health in Pain
- Vol. 166 (7) , 1662-1679
Open AccessModelling inflammation-induced peripheral sensitization in a dish—more complex than expected?
Peripheral sensitization of nociceptors is believed to be a key driver of chronic pain states. Here, we sought to study the effects of a modified version of inflammatory soup on the excitability of human stem cell–derived sensory neurons. For this, we used a preexisting and a novel stem cell line, modified to stably express the calcium sensor GCamP6f. Upon treatment with inflammatory soup, we observed no changes in neuronal transcription or functional responses upon calcium imaging and only a very minor increase in resting membrane potential (RMP) via whole cell patch clamping: control RMP (−71.31 ± 1.1 mV) vs inflammatory soup RMP (−67.74 ± 1.29 mV), uncorrected 2-tailed independent samples t test, P = 0.0383. Similarly, small changes were observed when treating mouse primary sensory neurons with inflammatory soup. A semi-systematic reexamination of past literature further indicated that observed effects of inflammatory mediators on dissociated sensory neuron cultures are generally small. We conclude that modelling inflammation-induced peripheral sensitization in vitro is nontrivial and will require careful selection of mediators and/or more complex, longitudinal multicellular setups. Especially in the latter, our novel GCamP6f-induced pluripotent stem cell line may be of value.
- Open Access
Fibroblast–Neuron Interactions Driving Persistent Pain in Rheumatoid Arthritis (FiND-Pain RA) - a study protocol
Introduction Pain in patients with rheumatoid arthritis (RA) is an unmet clinical need. Targeting joint inflammation with disease modifying antirheumatic drugs (DMARDs) has not resulted in the anticipated reduction in pain for many patients. This can partly be explained by the concept of central sensitisation whereby spinal and supraspinal pathways have a lower threshold of activation leading to increased perception of pain. Synovial stromal cells such as fibroblasts are also thought to play a role through peripheral sensitisation of nerves in the joint. Synovial fibroblasts are known to produce pro-algesic mediators such as interleukin 6 (IL-6) and nerve growth factor (NGF) at the mRNA level. These pro-algesic mediators could activate sensory nerve fibres that send signals from the joint to the spinal cord, thereby driving persistent pain in RA. The purpose of this study is to evaluate which pro-algesic mediators are produced by lining versus sublining fibroblasts and whether the level of these mediators correlates with clinical measures of pain in patients with RA. Methods and analysis FiND-Pain RA is a multi-centre observational study which will recruit 50 patients with seropositive RA who attend the rheumatology department of Guy’s and St Thomas’ Hospital, London and the Nuffield Orthopaedic Centre, Oxford. Clinical examination, pain-focused patient reported outcome measures (PROMs), ultrasound examination and ultrasound guided synovial biopsy of the knee will be performed. The levels of known and putative pro-algesic mediators will be measured in fibroblasts from the lining and sublining layer of the synovium. The location and spatial morphology of sensory nerve fibres and their proximity to lining and sub-lining fibroblasts will be characterized. The primary outcome will be to determine whether the knee pain scores of participants correlate with the level of LIF, a novel putative pain-mediator expressed in sub-lining fibroblasts. The secondary outcomes will be to determine whether other pro-algesic mediators produced by lining or sub-lining fibroblasts correlate with clinical measures of pain and to assess the location and proximity of sensory nerve fibres to lining versus sub-lining fibroblasts. Ethics and dissemination The study has been approved by the Bromley Research Ethics Committee (REC: 21/LO/0712). The findings of this study will be disseminated through open-access publications, as well as scientific and clinical conferences.
Open AccessFibroblast–Neuron Interactions Driving Persistent Pain in Rheumatoid Arthritis (FiND-Pain RA) - a study protocol
Introduction Pain in patients with rheumatoid arthritis (RA) is an unmet clinical need. Targeting joint inflammation with disease modifying antirheumatic drugs (DMARDs) has not resulted in the anticipated reduction in pain for many patients. This can partly be explained by the concept of central sensitisation whereby spinal and supraspinal pathways have a lower threshold of activation leading to increased perception of pain. Synovial stromal cells such as fibroblasts are also thought to play a role through peripheral sensitisation of nerves in the joint. Synovial fibroblasts are known to produce pro-algesic mediators such as interleukin 6 (IL-6) and nerve growth factor (NGF) at the mRNA level. These pro-algesic mediators could activate sensory nerve fibres that send signals from the joint to the spinal cord, thereby driving persistent pain in RA. The purpose of this study is to evaluate which pro-algesic mediators are produced by lining versus sublining fibroblasts and whether the level of these mediators correlates with clinical measures of pain in patients with RA. Methods and analysis FiND-Pain RA is a multi-centre observational study which will recruit 50 patients with seropositive RA who attend the rheumatology department of Guy’s and St Thomas’ Hospital, London and the Nuffield Orthopaedic Centre, Oxford. Clinical examination, pain-focused patient reported outcome measures (PROMs), ultrasound examination and ultrasound guided synovial biopsy of the knee will be performed. The levels of known and putative pro-algesic mediators will be measured in fibroblasts from the lining and sublining layer of the synovium. The location and spatial morphology of sensory nerve fibres and their proximity to lining and sub-lining fibroblasts will be characterized. The primary outcome will be to determine whether the knee pain scores of participants correlate with the level of LIF, a novel putative pain-mediator expressed in sub-lining fibroblasts. The secondary outcomes will be to determine whether other pro-algesic mediators produced by lining or sub-lining fibroblasts correlate with clinical measures of pain and to assess the location and proximity of sensory nerve fibres to lining versus sub-lining fibroblasts. Ethics and dissemination The study has been approved by the Bromley Research Ethics Committee (REC: 21/LO/0712). The findings of this study will be disseminated through open-access publications, as well as scientific and clinical conferences.